FDA Advisory Panel Recommends Six Peptides for Compounding List

The narrow committee votes went against the warnings of FDA staff scientists.

The FDA Pharmacy Compounding Advisory Committee recommended six of seven reviewed peptides for the 503A Bulks List, a decision that may reopen legal compounding pathways for popular regenerative therapies but provides no immediate regulatory relief for clinical practice. During its meetings on July 23-24, 2026, the advisory committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the bulk compounding list. These recommendations directly opposed the uniform advice of FDA staff scientists, who argued that clinical data is far too scarce and warned that existing studies are too short and underpowered. For example, staff scientists pointed out that BPC-157 has only five clinical trials on record.

The committee votes were exceptionally tight. BPC-157, KPV, and TB-500 all passed with narrow 8-6 votes and one abstention, while MOTS-c passed 7-5 with two abstentions. Conversely, the committee rejected emideltide, also known as delta sleep-inducing peptide, in a close 7-6 vote with one abstention.

For practice owners navigating the highly demanded peptide landscape, the immediate operational reality is unchanged. Compounding these peptides remains prohibited until the FDA formally accepts the committee recommendations and completes the mandatory notice-and-comment rulemaking. While external political factors exist, including HHS Secretary Robert F. Kennedy Jr. stating he is "a big fan" of these substances, clinics must wait for official federal rules to be finalized before sourcing or administering these therapies.

Source: American Journal of Managed Care, https://www.ajmc.com/view/fda-advisory-committee-recommends-6-of-7-peptides-for-compounding-list-against-staff-wishes